Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4737676 | 1.00 | MEN1 (0.36) | MEN1KMT2AHRH3KCNH2ACE | |
| SCHEMBL17658844 | 0.82 | DRD2 (0.42) | HRH3ACEOPRM1OPRK1MAOA | |
| SCHEMBL26504659 | 0.82 | HRH3 (0.34) | MEN1KMT2AHRH3KCNH2ACE | |
| SCHEMBL19440241 | 0.81 | ACE (0.38) | MEN1KMT2AHRH3KCNH2ACE | |
| SCHEMBL13267985 | 0.79 | NOTUM (0.39) | MEN1KMT2AHRH3KCNH2OPRM1 | |
| SCHEMBL13416638 | 0.79 | MAOA (0.39) | MEN1KMT2AACEOPRM1OPRK1 | |
| SCHEMBL13711153 | 0.79 | NOTUM (0.39) | MEN1KMT2AHRH3KCNH2OPRM1 | |
| SCHEMBL12650870 | 0.79 | MAOA (0.39) | MEN1KMT2AACEOPRM1OPRK1 | |
| SCHEMBL23034795 | 0.75 | HRH3 (0.37) | MEN1KMT2AHRH3KCNH2ACE | |
| SCHEMBL21323509 | 0.75 | MEN1 (0.34) | MEN1KMT2AHRH3KCNH2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023165943-A1 | 3-ALKYNYL CARBOXAMIDES AS AEP MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-09-07 | — | — | WO | disclosed |
| US-8987306-B2 | Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-03-24 | — | — | US | disclosed |
| US-20100179119-A1 | Inhibitors of Integrin Alpha2Beta1 Based on Prolyl Diaminopropionic Acid Scaffold | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179119-A1 | Inhibitors of Integrin Alpha2Beta1 Based on Prolyl Diaminopropionic Acid Scaffold | ITGA2B, ITGA2, ITGB2 | MEN1 4305/4885KMT2A 2860/4885HRH3 1217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.